{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:09:26Z","timestamp":1771423766475,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Jiading District Health Commission","award":["grant no. GWGZLXK-2023-01"],"award-info":[{"award-number":["grant no. GWGZLXK-2023-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40273-025-01584-y","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:44:22Z","timestamp":1769525062000},"page":"343-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Public Health Impact and Cost-Effectiveness of Routine and Catch-Up Human Papillomavirus Vaccination in Girls and Women in Selected Regions of China: A Model-Based Study"],"prefix":"10.1007","volume":"44","author":[{"given":"Xiaoya","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abram L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4651-9433","authenticated-orcid":false,"given":"Yihan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"1584_CR1","unstructured":"Markowitz LE, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(Rr-05):1\u201330."},{"issue":"1","key":"1584_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","volume":"16","author":"EM Burd","year":"2003","unstructured":"Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1\u201317.","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"1584_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","volume":"41","author":"HW Chesson","year":"2014","unstructured":"Chesson HW, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660\u20134.","journal-title":"Sex Transm Dis"},{"issue":"2","key":"1584_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/14760584.2019.1568876","volume":"18","author":"M Lehtinen","year":"2019","unstructured":"Lehtinen M, et al. Eradication of human papillomavirus and elimination of HPV-related diseases\u2014scientific basis for global public health policies. Expert Rev Vaccines. 2019;18(2):153\u201360.","journal-title":"Expert Rev Vaccines"},{"key":"1584_CR5","unstructured":"International Agency for Research on Cancer. Incidence, mortality and prevalence by cancer site in China. [cited 2025 Feb 17]. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/160-china-fact-sheet.pdf."},{"key":"1584_CR6","unstructured":"Department of Health and Immunization Programs. Notice on Matters Concerning the Inclusion of Human Papillomavirus Vaccine in the National Immunization Program. [cited 2025 November 20th]. https:\/\/www.ndcpa.gov.cn\/jbkzzx\/c100014\/common\/content\/content_1983714327087452160.html."},{"key":"1584_CR7","unstructured":"Baidu Baike. Cecolin 9\u00ae. [cited 2025 July 7]. https:\/\/baike.baidu.com\/item\/%E9%A6%A8%E5%8F%AF%E5%AE%81%C2%AE%209\/65745254."},{"issue":"48","key":"1584_CR8","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1016\/j.vaccine.2022.10.022","volume":"40","author":"Y Shu","year":"2022","unstructured":"Shu Y, et al. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20\u201345 years: a randomized, blinded, controlled with Gardasil (type 6\/11\/16\/18), phase III non-inferiority clinical trial. Vaccine. 2022;40(48):6947\u201355.","journal-title":"Vaccine"},{"issue":"11","key":"1584_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S1473-3099(23)00275-X","volume":"23","author":"FC Zhu","year":"2023","unstructured":"Zhu FC, et al. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial. Lancet Infect Dis. 2023;23(11):1313\u201322.","journal-title":"Lancet Infect Dis"},{"key":"1584_CR10","unstructured":"WHO. HPV vaccine included in national immunization programme [cited 2025 May 7]. https:\/\/app.powerbi.com\/view?r=eyJrIjoiNDIxZTFkZGUtMDQ1Ny00MDZkLThiZDktYWFlYTdkOGU2NDcwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9."},{"key":"1584_CR11","unstructured":"Department of Industry and Information Technology of Heilongjiang Province. Free HPV vaccination has covered about 40% of eligible girls across the country [cited 2025 May 7]. https:\/\/gxt.hlj.gov.cn\/gxt\/c106970\/202411\/c00_31784157.shtml."},{"key":"1584_CR12","unstructured":"World Health Organization. Vaccination schedule for Human papilloma virus [cited 2025 May 7]. https:\/\/immunizationdata.who.int\/pages\/schedule-by-disease\/hpv.html?ISO_3_CODE=&TARGETPOP_GENERAL=."},{"key":"1584_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv282","author":"M Brisson","year":"2016","unstructured":"Brisson M, et al. Health and economic impact of switching from a 4-valent to a 9-valent hpv vaccination program in the United States. J Natl Cancer Inst. 2016. https:\/\/doi.org\/10.1093\/jnci\/djv282.","journal-title":"J Natl Cancer Inst"},{"key":"1584_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12962-017-0073-8","volume":"15","author":"FS Mennini","year":"2017","unstructured":"Mennini FS, et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff Resour Alloc. 2017;15:11.","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"1584_CR15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s12879-017-2592-5","volume":"17","author":"X Mo","year":"2017","unstructured":"Mo X, et al. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017;17(1):502.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1584_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12889-022-13056-5","volume":"22","author":"L Zhou","year":"2022","unstructured":"Zhou L, et al. Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model. BMC Public Health. 2022;22(1):777.","journal-title":"BMC Public Health"},{"issue":"11","key":"1584_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031186","volume":"9","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Ni W, Wu J. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis. BMJ Open. 2019;9(11):e031186.","journal-title":"BMJ Open"},{"key":"1584_CR18","unstructured":"Innovation Lab for Vaccine Delivery Research. China launches trial of HPV vaccine [cited 2025 Feb 17]. https:\/\/vaxlab.dukekunshan.edu.cn\/evidence-db-expert\/hpv-vaccine-policy-advocacy-evidence-repository\/chinas-pilot-program-for-hpv-vaccine\/."},{"key":"1584_CR19","unstructured":"Tencent News. A comprehensive summary of the per capita GDP of 333 prefecture-level cities across China in 2023 [cited 2025 May 7]. https:\/\/news.qq.com\/rain\/a\/20241223A08DTQ00."},{"issue":"1","key":"1584_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/14760584.2024.2322543","volume":"23","author":"C Palmer","year":"2024","unstructured":"Palmer C, et al. Cost-effectiveness of nonavalent HPV vaccination in the Netherlands. Expert Rev Vaccines. 2024;23(1):312\u201323.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"1584_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.vhri.2013.02.001","volume":"2","author":"K Yamabe","year":"2013","unstructured":"Yamabe K, et al. The cost-effectiveness analysis of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) for Females in Japan. Value Health Reg Issues. 2013;2(1):92\u20137.","journal-title":"Value Health Reg Issues"},{"key":"1584_CR22","unstructured":"Health Information and Quality Authority (HIQA). Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys [cited 2025 Feb 17]. https:\/\/www.hiqa.ie\/sites\/default\/files\/2018-12\/HTA-for-HPV-Vaccination-boys.pdf."},{"issue":"46","key":"1584_CR23","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","volume":"29","author":"HW Chesson","year":"2011","unstructured":"Chesson HW, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443\u201350.","journal-title":"Vaccine"},{"key":"1584_CR24","unstructured":"Jiangsu Provincial Bureau of Statistics. 2020 Jiangsu population census yearbook [cited 2025 May 7]. https:\/\/tj.jiangsu.gov.cn\/2020pcnj\/zk\/indexch.htm."},{"key":"1584_CR25","unstructured":"Guangzhou Municipal Statistics Bureau. 2020 Guangzhou population census yearbook [cited 2025 Feb 17]. https:\/\/tjj.gz.gov.cn\/stats_newtjyw\/tjsj\/pcsj\/d7crkpc\/content\/post_8711587.html."},{"key":"1584_CR26","unstructured":"Sichuan Provincial Bureau of Statistics. 2020 Sichuan population census yearbook [cited 2025 May 7]. https:\/\/tjj.sc.gov.cn\/scstjj\/rkpcnew\/2020\/zk\/indexce.htm."},{"key":"1584_CR27","unstructured":"Hebei Provincial Bureau of Statistics. 2020 Hebei population census yearbook [cited 2025 May 7]. http:\/\/tjj.hebei.gov.cn\/extra\/col20\/rkpc2020\/indexch.htm."},{"key":"1584_CR28","unstructured":"Hebei Provincial Bureau of Statistics. 2023 Hebei population statistical yearbook [cited 2025 May 7]. http:\/\/tjj.hebei.gov.cn\/hetj\/tjnj\/2023\/zk\/indexch.htm."},{"key":"1584_CR29","unstructured":"Guangzhou Municipal Statistics Bureau. 2023 Guangzhou Statistical Yearbook [cited 2025 Feb 17]. https:\/\/tjj.gz.gov.cn\/datav\/admin\/home\/www_nj\/2023\/index.html."},{"key":"1584_CR30","unstructured":"Sichuan Provincial Bureau of Statistics. 2023 Sichuan Statistical Yearbook [cited 2025 May 7]. https:\/\/tjj.sc.gov.cn\/scstjj\/tjnjnew\/2023\/zk\/indexch.htm."},{"key":"1584_CR31","unstructured":"Jiangsu Provincial Bureau of Statistics. 2023 Jiangsu Statistical Yearbook [cited 2025 May 7]. https:\/\/tj.jiangsu.gov.cn\/2023\/indexc.htm."},{"issue":"5","key":"1584_CR32","first-page":"321","volume":"50","author":"X Yue","year":"2017","unstructured":"Yue X, Gong X, Li J, Teng F, Jiang N, Men P, et al. Epidemiological features of condyloma acuminatum in national sexually transmitted disease surveillance sites in China from 2008 to 2016. Chin J Dermatol. 2017;50(5):321\u20135.","journal-title":"Chin J Dermatol"},{"key":"1584_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317707373","author":"W Wang","year":"2017","unstructured":"Wang W, et al. Distribution and attribution of high-risk human papillomavirus genotypes in cervical precancerous lesions in China. Tumour Biol. 2017. https:\/\/doi.org\/10.1177\/1010428317707373.","journal-title":"Tumour Biol"},{"issue":"10451","key":"1584_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","volume":"404","author":"F Wei","year":"2024","unstructured":"Wei F, et al. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024;404(10451):435\u201344.","journal-title":"Lancet"},{"issue":"5","key":"1584_CR35","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, et al. Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555\u201367.","journal-title":"Lancet Glob Health"},{"issue":"19","key":"1584_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.46234\/ccdcw2024.080","volume":"6","author":"J Chen","year":"2024","unstructured":"Chen J, et al. Estimated human papillomavirus vaccine coverage among females 9\u201345 years of age\u2014China, 2017\u20132022. China CDC Wkly. 2024;6(19):413\u20137.","journal-title":"China CDC Wkly"},{"key":"1584_CR37","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020 [cited 2025 Feb 17]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/336583\/9789240014107-eng.pdf?sequence=1."},{"issue":"11","key":"1584_CR38","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","volume":"95","author":"LL Villa","year":"2006","unstructured":"Villa LL, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459\u201366.","journal-title":"Br J Cancer"},{"issue":"8","key":"1584_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"22","key":"1584_CR40","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.2016.17615","volume":"316","author":"OE Iversen","year":"2016","unstructured":"Iversen OE, et al. Immunogenicity of the 9-valent hpv vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA. 2016;316(22):2411\u201321.","journal-title":"JAMA"},{"issue":"8","key":"1584_CR41","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.jval.2024.04.014","volume":"27","author":"DL Li","year":"2024","unstructured":"Li DL, et al. EQ-5D-5L population norms for china derived from a national health survey. Value Health. 2024;27(8):1108\u201320.","journal-title":"Value Health"},{"issue":"7","key":"1584_CR42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/sextrans-2011-050161","volume":"88","author":"EL Conway","year":"2012","unstructured":"Conway EL, et al. Quality of life valuations of HPV-associated cancer health states by the general population. Sex Transm Infect. 2012;88(7):517\u201321.","journal-title":"Sex Transm Infect"},{"issue":"1","key":"1584_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12955-017-0748-z","volume":"15","author":"M Meregaglia","year":"2017","unstructured":"Meregaglia M, Cairns J. A systematic literature review of health state utility values in head and neck cancer. Health Qual Life Outcomes. 2017;15(1):174.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1584_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/sextrans-2018-053606","volume":"95","author":"KJ Ong","year":"2019","unstructured":"Ong KJ, et al. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Sex Transm Infect. 2019;95(1):28\u201335.","journal-title":"Sex Transm Infect"},{"issue":"11","key":"1584_CR45","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/ijc.31265","volume":"142","author":"I de Kok","year":"2018","unstructured":"de Kok I, et al. Quality of life assumptions determine which cervical cancer screening strategies are cost-effective. Int J Cancer. 2018;142(11):2383\u201393.","journal-title":"Int J Cancer"},{"key":"1584_CR46","unstructured":"Shandong Province Public Resources Electronic Trading Platform. Shandong Provincial Center for Disease Control and Prevention\u2019s Announcement on the Successful Purchase of Bivalent Human Papillomavirus (HPV) Vaccine for School-Age Girls Entering School in Shandong Province in 2024 [cited 2025 May 7]. https:\/\/ggzyjyzx.shandong.gov.cn\/art\/2024\/8\/2\/art_209869_10465231.html."},{"key":"1584_CR47","unstructured":"PAHO. PAHO Revolving Fund Vaccine Prices 2025 [cited 2025 May 7]. https:\/\/www.paho.org\/en\/documents\/revolving-fund-vaccine-prices-2025."},{"issue":"10","key":"1584_CR48","doi-asserted-by":"publisher","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","volume":"8","author":"Z Zou","year":"2020","unstructured":"Zou Z, et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Lancet Glob Health. 2020;8(10):e1335\u201344.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"1584_CR49","first-page":"345","volume":"27","author":"H Ninan","year":"2023","unstructured":"Ninan H, et al. Economic burden of human papilloma virus related diseases in China: a systematic review and synthetic analysis. Chin J Dis Control Prev. 2023;27(3):345.","journal-title":"Chin J Dis Control Prev"},{"issue":"6","key":"1584_CR50","doi-asserted-by":"publisher","first-page":"675","DOI":"10.21147\/j.issn.1000-9604.2023.06.11","volume":"35","author":"H Chen","year":"2023","unstructured":"Chen H, et al. Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: a nationwide multicenter cross-sectional study. Chin J Cancer Res. 2023;35(6):675\u201385.","journal-title":"Chin J Cancer Res"},{"issue":"4","key":"1584_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1584_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/ajco.13962","volume":"20","author":"S Arora","year":"2024","unstructured":"Arora S, Tuffaha H. Cost-effectiveness analysis of human papillomavirus vaccines for the prevention of cervical cancer in India. Asia Pac J Clin Oncol. 2024;20(1):55\u201362.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"1584_CR53","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e85","volume":"35","author":"W Termrungruanglert","year":"2024","unstructured":"Termrungruanglert W, et al. Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low\/middle-income country setting. J Gynecol Oncol. 2024;35(6):e85.","journal-title":"J Gynecol Oncol"},{"key":"1584_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106276","volume":"144","author":"A Portnoy","year":"2021","unstructured":"Portnoy A, et al. Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: a model-based analysis. Prev Med. 2021;144:106276.","journal-title":"Prev Med"},{"issue":"12","key":"1584_CR55","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.vaccine.2023.02.025","volume":"41","author":"MT Wahab","year":"2023","unstructured":"Wahab MT, et al. Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: a modelling-based cost-effectiveness analysis. Vaccine. 2023;41(12):1934\u201342.","journal-title":"Vaccine"},{"issue":"32","key":"1584_CR56","doi-asserted-by":"publisher","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","volume":"68","author":"E Meites","year":"2019","unstructured":"Meites E, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698\u2013702.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"1584_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12962-021-00328-x","volume":"19","author":"TH Cheung","year":"2021","unstructured":"Cheung TH, et al. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong. Cost Eff Resour Alloc. 2021;19(1):75.","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"1584_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12879-020-05632-0","volume":"21","author":"P Cody","year":"2021","unstructured":"Cody P, et al. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infect Dis. 2021;21(1):11.","journal-title":"BMC Infect Dis"},{"key":"1584_CR59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12962-019-0196-1","volume":"17","author":"J John","year":"2019","unstructured":"John J, Koerber F, Schad M. Differential discounting in the economic evaluation of healthcare programs. Cost Eff Resour Alloc. 2019;17:29.","journal-title":"Cost Eff Resour Alloc"},{"issue":"10197","key":"1584_CR60","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","volume":"394","author":"M Drolet","year":"2019","unstructured":"Drolet M, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497\u2013509.","journal-title":"Lancet"},{"key":"1584_CR61","doi-asserted-by":"crossref","unstructured":"M.d.C. T, et al. Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India. BMJ Glob Health. 2023;8(11).","DOI":"10.1136\/bmjgh-2023-012580"},{"key":"1584_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12111248","author":"G Umutesi","year":"2024","unstructured":"Umutesi G, et al. The potential impact of a single-dose HPV vaccination schedule on cervical cancer outcomes in Kenya: a mathematical modelling and health economic analysis. Vaccines (Basel). 2024. https:\/\/doi.org\/10.3390\/vaccines12111248.","journal-title":"Vaccines (Basel)"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01584-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01584-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:30:11Z","timestamp":1771421411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01584-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01584-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YL received the grant from MSD China (4-valent and 9-valent HPV vaccines licensed in China\u2019s mainland) for research in modeling and health economics of HPV vaccination in adolescent girls, and consultation fees from Walwax Biotechnology Co., Ltd (2-valent HPV vaccine licensed in China\u2019s mainland, and a 9-valent HPV vaccine candidate in the clinical trial) and Xiamen Innovax Biotech Co., Ltd (2-valent and 9-valent HPV vaccines licensed in China\u2019s mainland).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The dataset analyzed during the current study is available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"This study was a modeling study using de-identified published data as model inputs. No ethical approval or informed consent was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"YL and XF conceived of this study. XF and FW developed and modified the evaluation model. QZ, XF, FW, and YX collected the data and conducted the modeling. XF drafted initial manuscript. YL, YY, QZ, and ALW critically revised the manuscript and helped interpret data. All authors reviewed the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}